4th Night–Demonstrators March in Charlotte, Atlanta to
4th Night–Demonstrators March in Charlotte, Atlanta to Protest Police Shootings
CHARLOTTE, N.C. (AP) — For a fourth night, there are protests in Charlotte over the fatal shooting of a black man by a police officer.
Demonstrators gathered at a park and then marched into the business district. One had a banner that said “Just Release the Tapes.”
Protesters have sought the release of police footage of the shooting earlier this week of Keith Lamont Scott by a police officer.
Hillary Clinton’s campaign says she has decided to postpone her planned trip to Charlotte, North Carolina, on Sunday after hearing from community leaders.
Clinton announced earlier Friday that she would travel to Charlotte in the aftermath of the shooting of a black man by a Charlotte police officer.
But Clinton’s campaign now says that after further discussions with community leaders, the Democratic presidential nominee will postpone the trip to avoid straining the city’s resources.
Clinton’s decision came after Charlotte Mayor Jennifer Roberts told CNN that Clinton should postpone her visit because the city’s security resources were stretched thin.
Clinton now plans to visit Charlotte on Sunday, October 2.
Meanwhile in Atlanta, hundreds marched in an NAACP protest against police shootings.
Marchers took to the streets after a rally at the National Center for Civil and Human Rights museum Friday evening. Many held signs reading “Black Lives Matter” and chanted “We’re ready, we’re ready for y’all.”
NAACP state President Francys Johnson and lawyer Mawuli Mel Davis led the protest. No police were present, but volunteers walked ahead of demonstrators and blocked off intersections for marchers.
The peaceful march in Atlanta comes after Scott was fatally shot by an officer in Charlotte. In Oklahoma, 40-year-old Terence Crutcher was shot to death by Tulsa Officer Betty Shelby.
Shelby is charged with first-degree manslaughter.
Featured stocks: Coffee Shoppe
For conservative debate: "Keeping it Real"
Game Changing stock $SHMP
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...
Continue Reading
The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...
Continue Reading
Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...
Continue Reading
GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...
Continue Reading
Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...
Continue Reading
Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...
Continue Reading
Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...
Continue Reading
Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...
Continue Reading
The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...
Continue Reading
Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....
Continue Reading
Top 5 Most Recently Viewed Articles
The conformal coatings market surged ahead with projections showing it could reach USD 1.7 billion by 2032. This translates into a compound annual growth rate (CAGR) of 5.7% from 2024 to 2032, driven primarily by advancements in electronic protection technologies. Traders had better keep their eyes peeled—this ain't just a bump; it's a substantial shift. What’s...
Continue Reading
Japan Mobile Battery Market Overview The mobile battery market in Japan is witnessing significant growth, with a valuation of JPY 207.96 billion in 2024 and projected to escalate to JPY 358.97 billion by 2033, marking a compound annual growth rate (CAGR) of 6.48% from 2025 to 2033. This growth trajectory highlights not only increasing consumer demands but also rapidly...
Continue Reading
Givastomig's Advances in Gastric Cancer Research I-Mab (NASDAQ: IMAB), a biotech firm focused on developing cancer immunotherapies, recently presented exciting results from its Phase 1 clinical trial involving givastomig. This innovative bispecific antibody immunostimulant was unveiled at a prominent medical conference, demonstrating its effectiveness in treating advanced...
Continue Reading
Rani Therapeutics Engages with Chugai Pharmaceutical Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) recently announced a significant collaborative effort with Chugai Pharmaceutical Co., Ltd., resulting in an enthusiastic response from investors. This collaboration aims to utilize Rani's innovative RaniPill oral drug delivery system alongside Chugai's experimental...
Continue Reading
Revizto Introduces a Fresh Brand Identity As project complexities continue to rise in the construction industry, Revizto is making important modifications to its public image. The renowned collaboration platform, specifically designed for the Architecture, Engineering, Construction, and Operations (AECO) sectors, recently unveiled its refreshed brand identity,...
Continue Reading